We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PACS vs. MEDP: Which Stock Is the Better Value Option?
Read MoreHide Full Article
Investors interested in Medical Services stocks are likely familiar with PACS Group, Inc. (PACS - Free Report) and Medpace (MEDP - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
PACS Group, Inc. and Medpace are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. Investors should feel comfortable knowing that PACS likely has seen a stronger improvement to its earnings outlook than MEDP has recently. However, value investors will care about much more than just this.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
PACS currently has a forward P/E ratio of 15.28, while MEDP has a forward P/E of 29.38. We also note that PACS has a PEG ratio of 1.02. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. MEDP currently has a PEG ratio of 1.94.
Another notable valuation metric for PACS is its P/B ratio of 4.09. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, MEDP has a P/B of 12.36.
These are just a few of the metrics contributing to PACS's Value grade of A and MEDP's Value grade of C.
PACS sticks out from MEDP in both our Zacks Rank and Style Scores models, so value investors will likely feel that PACS is the better option right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PACS vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with PACS Group, Inc. (PACS - Free Report) and Medpace (MEDP - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
PACS Group, Inc. and Medpace are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. Investors should feel comfortable knowing that PACS likely has seen a stronger improvement to its earnings outlook than MEDP has recently. However, value investors will care about much more than just this.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
PACS currently has a forward P/E ratio of 15.28, while MEDP has a forward P/E of 29.38. We also note that PACS has a PEG ratio of 1.02. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. MEDP currently has a PEG ratio of 1.94.
Another notable valuation metric for PACS is its P/B ratio of 4.09. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, MEDP has a P/B of 12.36.
These are just a few of the metrics contributing to PACS's Value grade of A and MEDP's Value grade of C.
PACS sticks out from MEDP in both our Zacks Rank and Style Scores models, so value investors will likely feel that PACS is the better option right now.